LXEO vs. TRML, ITOS, TCRX, REPL, ADPT, SLDB, AURA, CCCC, ALVO, and TNYA
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Tourmaline Bio (TRML), iTeos Therapeutics (ITOS), TScan Therapeutics (TCRX), Replimune Group (REPL), Adaptive Biotechnologies (ADPT), Solid Biosciences (SLDB), Aura Biosciences (AURA), C4 Therapeutics (CCCC), Alvotech (ALVO), and Tenaya Therapeutics (TNYA). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
Tourmaline Bio has higher earnings, but lower revenue than Lexeo Therapeutics. Tourmaline Bio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tourmaline Bio received 4 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users.
Lexeo Therapeutics' return on equity of -30.86% beat Tourmaline Bio's return on equity.
In the previous week, Tourmaline Bio had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 11 mentions for Tourmaline Bio and 8 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.89 beat Tourmaline Bio's score of 0.11 indicating that Tourmaline Bio is being referred to more favorably in the media.
Tourmaline Bio presently has a consensus target price of $61.80, suggesting a potential upside of 320.98%. Lexeo Therapeutics has a consensus target price of $20.80, suggesting a potential upside of 50.07%. Given Lexeo Therapeutics' higher possible upside, equities analysts clearly believe Tourmaline Bio is more favorable than Lexeo Therapeutics.
91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Tourmaline Bio beats Lexeo Therapeutics on 10 of the 12 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
